These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
302 related items for PubMed ID: 26559391
21. New-onset and relapsed thrombotic microangiopathy post-COVID-19 vaccination. Ma Q, Xu G. J Med Virol; 2023 Jul; 95(7):e28946. PubMed ID: 37436788 [Abstract] [Full Text] [Related]
22. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM. Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363 [Abstract] [Full Text] [Related]
24. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495 [Abstract] [Full Text] [Related]
25. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy. Che M, Moran SM, Smith RJ, Ren KYM, Smith GN, Shamseddin MK, Avila-Casado C, Garland JS. Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703 [Abstract] [Full Text] [Related]
26. Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review. Malgaj Vrečko M, Aleš Rigler A, Večerić-Haler Ž. Int J Mol Sci; 2022 Sep 25; 23(19):. PubMed ID: 36232608 [Abstract] [Full Text] [Related]
27. [Atypical HUS caused by complement-related abnormalities]. Yoshida Y, Matsumoto M. Rinsho Ketsueki; 2015 Feb 25; 56(2):185-93. PubMed ID: 25765799 [Abstract] [Full Text] [Related]
28. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Nephrology (Carlton); 2018 Jun 25; 23(6):507-517. PubMed ID: 29419916 [Abstract] [Full Text] [Related]
29. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Mannucci PM, Cugno M. Thromb Res; 2015 Nov 25; 136(5):851-4. PubMed ID: 26386489 [Abstract] [Full Text] [Related]
30. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Trojnar E, Józsi M, Szabó Z, Réti M, Farkas P, Kelen K, Reusz GS, Szabó AJ, Garam N, Mikes B, Sinkovits G, Mező B, Csuka D, Prohászka Z. Front Immunol; 2019 Nov 25; 10():240. PubMed ID: 30858847 [Abstract] [Full Text] [Related]
31. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Res Pract Thromb Haemost; 2017 Jul 25; 1(1):69-80. PubMed ID: 30046676 [Abstract] [Full Text] [Related]
33. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Hum Mutat; 2010 Jun 08; 31(6):E1445-60. PubMed ID: 20513133 [Abstract] [Full Text] [Related]
34. The role of von Willebrand factor in thrombotic microangiopathy. Noone DG, Riedl M, Licht C. Pediatr Nephrol; 2018 Aug 08; 33(8):1297-1307. PubMed ID: 28748411 [Abstract] [Full Text] [Related]
35. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Blood; 2019 Sep 26; 134(13):1095-1105. PubMed ID: 31409673 [Abstract] [Full Text] [Related]
36. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Williams LA, Marques MB, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Am J Clin Pathol; 2016 Feb 26; 145(2):158-65. PubMed ID: 27124904 [Abstract] [Full Text] [Related]
37. Modified Ham test for atypical hemolytic uremic syndrome. Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Blood; 2015 Jun 04; 125(23):3637-46. PubMed ID: 25862562 [Abstract] [Full Text] [Related]
38. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Clin J Am Soc Nephrol; 2010 Oct 04; 5(10):1844-59. PubMed ID: 20595690 [Abstract] [Full Text] [Related]
39. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P, Limburg Renal Registry. Kidney Int; 2017 Jun 04; 91(6):1420-1425. PubMed ID: 28187980 [Abstract] [Full Text] [Related]
40. Genetics of atypical hemolytic uremic syndrome (aHUS). Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Semin Thromb Hemost; 2014 Jun 04; 40(4):422-30. PubMed ID: 24799305 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]